Foreseen Biotechnology (CN)

https://www.foreseenbio.com

We are an emerging biotechnology company that pioneered a high throughput integrated translational proteomics platform powered by AI-based data analytical system to accelerate discovery of novel targets for therapeutics and diagnostics that are clinically relevant. We are building a pipeline of novel product candidates for the diagnosis and treatment of cancer, inflammatory/autoimmune diseases and neurological disorders. Foreseen Biotechnology is incubated by Nest.Bio Ventures. *

	Start	2021-08-01 established
	Industry	BIOTECH
	Industry 2	antibody-drug conjugate (ADC)

	Region	Shanghai
	Country	China
	City	n. a. Shanghai
		Address record changed: 2024-07-14

Basic data	Employees	n. a.

		* Document for »About Section«: Ipsen S.A.. (7/11/24). "Press Release: Ipsen and Foreseen Biotechnology Announce Exclusive Global Licensing Agreement for Antibody-Drug Conjugate with First-in-Class Potential". Paris.

		Record changed: 2024-08-24

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Foreseen Biotechnology (CN)

[1] Ipsen S.A.. (7/11/24). "Press Release: Ipsen and Foreseen Biotechnology Announce Exclusive Global Licensing Agreement for Antibody-Drug Conjugate with First-in-Class Potential". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]